Startups
About two years ago, former president and chief executive officer of Sarepta Therapeutics, Chris Garabedian, formed Xontogeny, a biotech accelerator. Xontogeny was founded to support life science technology startups.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend. This morning BenevolentAI snagged $115 million.
Alexandria Real Estate Equities, an urban office real estate investment company specializing in the life sciences, is expanding its Alexandria LaunchLabs into the East Cambridge, Massachusetts area.
Biotech investor Vivek Ramaswamy has launched another company. This time his company, dubbed Genevant, will focus on the development of RNA-based therapies and is the combined product of Roivant Sciences and Arbutus Biopharma Corporation.
After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
PRESS RELEASES